Korsana Biosciences, Inc. (KRSA)
32.83
-2.16
(-6.17%)
USD |
NASDAQ |
Sep 21, 16:00
33.09
+0.26
(+0.79%)
After-Hours: 20:00
Korsana Biosciences Net Income (Quarterly) : -1.755M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.755M |
| March 31, 2026 | -3.177M |
| December 31, 2025 | -0.799M |
| September 30, 2025 | -0.976M |
| June 30, 2025 | -0.324M |
| March 31, 2025 | -1.429M |
| December 31, 2024 | 0.53M |
| September 30, 2024 | -0.723M |
| June 30, 2024 | -1.322M |
| March 31, 2024 | -1.542M |
| December 31, 2023 | -1.694M |
| September 30, 2023 | -5.908M |
| June 30, 2023 | -1.803M |
| March 31, 2023 | -3.187M |
| December 31, 2022 | -4.323M |
| September 30, 2022 | -4.407M |
| June 30, 2022 | -13.39M |
| March 31, 2022 | -12.98M |
| Date | Value |
|---|---|
| December 31, 2021 | -10.78M |
| September 30, 2021 | -11.29M |
| June 30, 2021 | -16.18M |
| March 31, 2021 | -13.40M |
| December 31, 2020 | -19.23M |
| September 30, 2020 | -18.81M |
| June 30, 2020 | -19.53M |
| March 31, 2020 | -20.23M |
| December 31, 2019 | -26.06M |
| September 30, 2019 | -27.32M |
| June 30, 2019 | -32.25M |
| March 31, 2019 | -37.38M |
| December 31, 2018 | -30.90M |
| September 30, 2018 | -29.29M |
| June 30, 2018 | -29.78M |
| March 31, 2018 | -25.28M |
| December 31, 2017 | -27.66M |
| September 30, 2017 | -25.19M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Climb Bio, Inc. | -13.50M |
| Q32 Bio, Inc. | -8.946M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.755M |
| EPS Diluted (Quarterly) | -2.890 |
| Enterprise Value | 19.88M |
| Earnings Yield | -35.82% |
| Normalized Earnings Yield | -35.82 |